ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy (updated)

ADC Therapeutics SA

11/07/2023 12:42

(Adds shares, details from company release in paragraphs 3 and
4)
       July 11 (Reuters) - ADC Therapeutics  ADCT.N  said on
Tuesday it had paused enrollments in a mid-stage study
evaluating its drug Zynlonta for treating a type of blood cancer
over safety concerns. 
    The company's U.S.-listed shares tumbled about 18% in
premarket trading. 
    ADC said it paused the enrolment after the review of data of
40 patients in the trial signaled potentially excessive
respiratory-related events, including seven deaths and five
serious adverse events.
    The cause of these events remains under further
investigation, the company said. 
    

 (Reporting by Raghav Mahobe in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Raghav.Mahobe@thomsonreuters.com;))